A research of efficacy and safety of aripiprazole treatment for the behavioral symptoms in subjects with pervasive developmental disordes.

A research of efficacy and safety of aripiprazole treatment for the behavioral symptoms in subjects with pervasive developmental disordes. - A reseach of aripiprazole treatment for the behavioral symptoms in subjects with pervasive developmental disordes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006558

Enrollment

Registered

2011-10-20

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pervasive Developmental Disorders

Interventions

continuous administration of aripiprazole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pervasive developmental disorders(PDD) based on the classifications in the diagnostic and statistical manual of mental disorders (DSM-IV)

Exclusion criteria

Exclusion criteria: 1. Children less than 6 years old. 2. Participants were excluded if they had a history of major medical or neurological illness including epilepsy, significant head trauma, or a lifetime history of alcohol or drug dependence.

Design outcomes

Primary

Measure	Time frame
Aberrant Behavior Checklist irritability	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026